Core Viewpoint - Shandong Weigao Blood Purification Products Co., Ltd. is planning to acquire 100% equity of Shandong Weigao Puri Pharmaceutical Packaging Co., Ltd. through a share issuance, which will make Weigao Puri a wholly-owned subsidiary of Weigao Blood Purification [1][3] Group 1: Transaction Details - The transaction involves Weigao Puri as the target and the counterparties include Weigao Group Medical Polymer Products Co., Ltd., Weihai Shengxi Enterprise Management Consulting Center (Limited Partnership), and Weihai Ruiming Enterprise Management Consulting Partnership (Limited Partnership) [1][2] - The transaction is expected to constitute a major asset restructuring and related party transaction, but will not change the actual controller of the company and does not constitute a reverse listing [3] Group 2: Company Background - Weigao Puri was established in 2018 and is primarily focused on providing comprehensive drug delivery solutions for global biopharmaceutical companies, being the first in China to obtain registration for pre-filled syringes [2] - Weigao Group, founded in 1988, is involved in medical devices and pharmaceuticals, covering various product lines including clinical care, orthopedics, blood purification, drug packaging, and medical intervention [1][2] Group 3: Financial Performance - Weigao Blood Purification has shown consistent revenue growth, with revenues of 3.426 billion, 3.532 billion, and 3.604 billion for the years 2022 to 2024, and net profits of 315 million, 442 million, and 449 million respectively [3] - In the first half of 2025, Weigao Blood Purification achieved revenue of 1.765 billion, an increase of 8.52% year-on-year, and a net profit of 220 million, up 10.11% year-on-year [3]
威高血净拟收购“自家人”威高普瑞100%股权，股票今起停牌